CSL’s problems run far deeper than the distraction of sacking a chief executive after the stunning revelation that around half the value of the $US11.7bn ($16.2bn) “transformational” Vifor deal has ...
After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...
The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the ...
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...
Vifor, part of Australian group CSL, made the proposal following a two-year investigation by the European Commission. The EU competition enforcer was concerned by Vifor's allegedly misleading ...
Vifor Pharma is losing a chief commercial officer but gaining a new chief medical officer in the form of Sanofi’s Klaus Henning Jensen. Jensen joins from the French Big Pharma where he was its global ...
Vifor Pharma has committed €25 million ($28 million) to a nephrology joint venture with Evotec. The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint ...
ST. GALLEN, Switzerland & HAMBURG, Germany--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Evotec SE today announced the launch of a 50:50 joint venture focused on the discovery and development of ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results